IMVT Projected Dividend Yield
Immunovant Inc ( NASDAQ : IMVT )Immunovant, Inc. is a clinical-stage immunology company. Co. is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. 21 YEAR PERFORMANCE RESULTS |
IMVT Dividend History Detail IMVT Dividend News IMVT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |